# Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection

> **NCT06621251** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Trellis Bioscience LLC** · enrollment: 60 (estimated)

## Conditions studied

- Prosthetic Joint Infections of Hip
- Prosthetic Joint Infections of Knee

## Interventions

- **DRUG:** TRL1068 (calpurbatug), a human monoclonal antibody
- **PROCEDURE:** DAIR

## Key facts

- **NCT ID:** NCT06621251
- **Lead sponsor:** Trellis Bioscience LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-08
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06621251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06621251, "Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06621251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*